Clinical Trial Update: A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 [Phase 1]

View source ↗

Summary

A Phase 1 study completed in overweight/obesity participants evaluating tolerability of BI 1820237 given alone or with Semaglutide or BI 456906.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• BI 1820237
• BI 456906
• semaglutide (semaglutide)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Healthy, Obesity | Phase 1 | Status: COMPLETED